Zepbound for Sleep Apnea: Why Women Get Missed, and What the Trial Found

Is Zepbound approved for sleep apnea?

Yes. On December 20, 2024, the FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and activity. It was the first drug approved for the condition. It does not replace a sleep study, and it does not mean you can put the CPAP machine in the closet.¹

That approval matters to mothers for two reasons that have nothing to do with each other. The first is clinical: sleep apnea in women is badly underdiagnosed, and the symptoms that point to it are the ones we have been trained to blame on children, hormones and the calendar. The second is financial: a sleep apnea diagnosis can move Zepbound out of the "weight loss" category that so many insurance plans refuse to pay for.

What SURMOUNT-OSA actually found

The approval rests on SURMOUNT-OSA, two 52-week trials published together in the New England Journal of Medicine. Trial 1 enrolled adults who were not using positive airway pressure (PAP). Trial 2 enrolled adults who already were. Everyone had moderate-to-severe apnea and obesity, and people received the highest dose they tolerated, 10 mg or 15 mg, or placebo.²

These were not borderline cases. Mean apnea-hypopnea index (AHI, the number of breathing pauses and shallow breaths per hour of sleep) was 51.5 events an hour in Trial 1 and 49.5 in Trial 2. That is close to one interrupted breath a minute, all night.

Source: the NEJM trial report² and the Zepbound prescribing information³.

The drug roughly halved the number of events. Participants in the trial also reported better sleep on validated questionnaires, and blood pressure, inflammation markers and body weight moved in the right direction too.² The honest framing is that about half of the people on tirzepatide got down to mild or no apnea, and about half did not.

Why so many women never get the diagnosis

Look at the last row of that table again. Two-thirds or more of the participants were men. That is not a design flaw so much as a mirror: trials recruit from people who have already been diagnosed, and the people who get diagnosed are mostly men.

The gap is old and it is large. A 1997 study in Sleep surveyed 4,925 employed adults and gave 1,090 of them overnight lab sleep studies. It estimated that 93% of women with moderate-to-severe sleep apnea had never been clinically diagnosed, against 82% of men.⁴ A structured review published this year in Sleep Medicine explains part of why. Women often show a lower AHI while carrying a heavy symptom load, and screening questionnaires built around the classic male picture miss them. The result is delayed referral and underdiagnosis.⁵

The classic picture is a man who snores loudly and nods off at his desk. Women are more likely to show up with something else:

In one sleep-lab series of 514 patients, the women were older and heavier at diagnosis than the men. Morning headache, nighttime urination, fatigue and depression were all more common in the women.⁶ Each of those symptoms has a dozen easier explanations for a mother of young children, which is precisely the problem.

Menopause shifts the odds again. The sex gap in prevalence narrows after menopause, which researchers read as a sign that hormones are protecting the airway before it.⁷ If you are in your forties, more tired than your schedule explains, and waking with a headache, ask for a sleep study by name. Do not wait for someone to suggest it.

Pregnancy and the postpartum year

Sleep-disordered breathing becomes more common as pregnancy goes on, and it is not harmless. In the nuMoM2b cohort of first-time mothers, it was present in 3.6% of women in early pregnancy and 8.3% by mid-pregnancy. Women who had it carried roughly twice the odds of preeclampsia and about three times the odds of gestational diabetes.⁸

None of that makes Zepbound a pregnancy drug. It is not used in pregnancy, and the label's guidance is covered in what the Zepbound label says about pregnancy. What it does mean is that snoring, gasping or crushing tiredness in pregnancy deserve a mention at your next prenatal visit. If you were told during pregnancy that your breathing was "probably the baby," and it is still happening a year later, that is worth a proper test.

Do you still need the CPAP?

Probably, at least for now. In Trial 2, participants stayed on their PAP and paused it only for the week before the final sleep study. The prescribing information states plainly that the trials did not test when, or whether, people who use PAP well should stop.³ Coming off a machine is a decision for a repeat sleep study and the clinician who prescribed it, not one to make because the scale moved.

Think of it this way. The drug lowers the number of events, mostly by lowering weight, but your airway anatomy does not change. For many women the realistic goal is a lower pressure setting or a milder diagnosis, not freedom from the mask.

What the diagnosis changes about coverage

This is where the indication earns its keep. A great many employer plans exclude drugs prescribed "for weight loss." A prescription written for moderate-to-severe obstructive sleep apnea is a different claim, and some of those plans will review it on its merits.

Medicare is clearer. In a March 2026 memo to drug plans, CMS said that people prescribed Zepbound for moderate-to-severe sleep apnea should keep getting coverage through Medicare Part D. Those people are not eligible for the new $50-a-month Medicare GLP-1 Bridge, which is reserved for weight management.⁹ So on Medicare the sleep study is the route in, not a detour.

What a plan will usually want to see is a sleep study showing moderate or severe apnea (an AHI of 15 or more), a documented BMI in the obesity range, and the prescription written for the OSA indication. We walk through the paperwork, and what to do if the answer is no, in how to get Zepbound covered with a metabolic diagnosis. If the plan still says no, the cash prices behind the manufacturer programs are the fallback.

Wegovy and Ozempic are not OSA drugs

Semaglutide can lower weight and, with it, apnea severity. But neither Wegovy nor Ozempic carries a sleep apnea indication. Wegovy's label covers weight, cardiovascular risk reduction and a liver disease called MASH.¹⁰ Ozempic is a type 2 diabetes drug. For coverage, that distinction is everything. A semaglutide prescription cannot use the OSA route, which is one of the practical reasons a woman with diagnosed apnea might end up on tirzepatide. For the wider comparison, see Zepbound vs Wegovy, and for the nights-and-tiredness side of these drugs, our piece on sleep on a GLP-1.